Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Forte Biosciences Inc FBRX

Healthcare Biotechnology
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases. The Company is advancing its product candidate, FB-102, which is a proprietary molecule with potentially broad autoimmune applications, including in such indications as graft-versus-host disease (GvHD), vitiligo, and alopecia areata (AA). The Company’s FB-102 program... see more

NDAQ:FBRX - Post Discussion

Forte Biosciences Inc > Forte Biosciences Reports Oversubscribed $53 Million Private
View:
Post by whytestocks on Nov 20, 2024 10:46am

Forte Biosciences Reports Oversubscribed $53 Million Private

Just In: $FBRX Forte Biosciences Reports Oversubscribed $53 Million Private Placement to Advance FB1022024-11-20 10:34:17 ET DENVER, Colo., Nov 20, 2024 ( 247marketnews.com )- Forte Biosciences (NASDAQ: FBRX ) reported that its $53 million equity financing, to support the continuing clinical advancement of FB102, was oversubscribed. Paul Wagner, Ph.D., Chairman and CEO of Forte ...FBRX - Forte Biosciences Reports Oversubscribed $53 Million Private Placement to Advance FB102
Be the first to comment on this post
Forte Biosciences Inc
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities